Bioventus (BVS) IPO Opens 16% Higher

Today's IPO for Bioventus (NASDAQ: BVS) opened for trading at $15.10 after pricing its initial public offering of 8,000,000 shares of Class A common stock at a public offering price of $13.00 per share.

Morgan Stanley, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are serving as joint lead book-running managers and as representatives of the underwriters for the proposed offering. Canaccord Genuity LLC is acting as lead manager for the offering.

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

You May Also Be Interested In

• SpaceX held talks to acquire AI coding startup Cognition - report
• K Wave Media prices $1M registered direct offering at $1.90 per share
• Indian fintech Navi to raise $100 million ahead of planned IPO